Physician profile
Amber L Flaherty
NPI 1093008336
$37,752.35
in general payments reported to CMS, 2019-2025
84 companies · $2,087 in 2025
The $2,087 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,381 · 2020: $5,517 · 2021: $6,111 · 2022: $11K · 2023: $7,673 · 2024: $4,473 · 2025: $2,087.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,275 · Long Term Medical Supply Or Device Loan: $299 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,584.17 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,275.00 |
| Long Term Medical Supply Or Device Loan | $299.10 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Global Blood Therapeutics, INC. | $11,791.38 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $5,957.80 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Clovis Oncology, INC. | $2,121.41 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $1,525.57 | 2019-2025 | |
| Pfizer INC. | $1,228.91 | 2019-2025 | |
| Janssen Biotech, INC. | $999.56 | 2019-2025 | Erleada, Darzalex, Imbruvica |
| Astrazeneca Pharmaceuticals LP | $976.39 | 2019-2025 | Imfinzi, Lynparza, Tagrisso |
| Daiichi Sankyo INC. | $971.19 | 2019-2025 | Enhertu, Injectafer, Vanflyta |
| Celgene Corporation | $908.42 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| E.R. Squibb & Sons, L.L.C. | $855.99 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Amgen INC. | $742.96 | 2019-2023 | Vectibix, Xgeva, Nplate |
| Exelixis INC. | $577.79 | 2021-2025 | Cabometyx |
| Genzyme Corporation | $569.36 | 2019-2025 | |
| Lilly USA, LLC | $482.24 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Genentech USA, INC. | $470.33 | 2019-2024 | Tecentriq, Alecensa, Rozlytrek |
Show all 82 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $454.13 | 2019-2025 | |
| Seagen INC. | $448.48 | 2020-2023 | Adcetris, Tukysa, Padcev |
| Incyte Corporation | $399.10 | 2022-2025 | Jakafi, Pemazyre, Monjuvi |
| Abbvie INC. | $337.34 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $315.36 | 2019-2025 | |
| Astellas Pharma US INC | $266.25 | 2022-2024 | Xospata, Padcev, Xtandi |
| Tersera Therapeutics LLC | $256.94 | 2022-2025 | Zoladex, Xermelo, Quzyttir |
| Blueprint Medicines Corporation | $255.10 | 2022-2025 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $231.28 | 2019-2025 | Fruzaqla, Alunbrig, Iclusig |
| Gilead Sciences, INC. | $224.98 | 2021-2025 | Trodelvy |
| Ipsen Biopharmaceuticals, INC | $215.82 | 2019-2025 | Onivyde, Somatuline Depot |
| Emd Serono, INC. | $209.08 | 2019-2023 | Tepmetko, Bavencio |
| Glaxosmithkline, LLC. | $208.49 | 2019-2025 | Zejula, Jemperli, Ojjaara |
| Adaptive Biotechnologies Corporation | $195.30 | 2022-2024 | Clonoseq |
| Array Biopharma INC | $183.80 | 2022-2024 | Braftovi, Mektovi, Lorbrena |
| Sobi, INC | $164.86 | 2022-2025 | |
| Stemline Therapeutics INC. | $161.73 | 2023-2025 | Orserdu |
| Genmab U.S., INC. | $154.16 | 2023-2025 | Epkinly, Tivdak |
| Pharmacyclics LLC, An Abbvie Company | $144.39 | 2021-2023 | Imbruvica, Epkinly |
| Sumitomo Pharma America, INC. | $142.76 | 2023-2024 | Orgovyx |
| Springworks Therapeutics, INC. | $133.44 | 2024-2025 | Ogsiveo |
| Karyopharm Therapeutics INC. | $131.16 | 2022-2024 | Xpovio |
| Puma Biotechnology, INC. | $128.84 | 2019-2024 | Nerlynx |
| Beigene USA, INC. | $123.41 | 2023-2025 | Brukinsa, Tevimbra |
| Sun Pharmaceutical Industries INC. | $121.90 | 2022-2023 | Odomzo, Yonsa |
| Regeneron Healthcare Solutions, INC. | $112.68 | 2019-2024 | Libtayo |
| Alexion Pharmaceuticals, INC. | $111.64 | 2022-2024 | Ultomiris |
| Pharmacosmos Therapeutics INC. | $104.81 | 2022-2025 | Monoferric |
| Rigel Pharmaceuticals, INC. | $104.11 | 2022-2024 | Rezlidhia, Tavalisse |
| Jazz Pharmaceuticals INC. | $90.47 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $89.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.02 | 2019-2022 | |
| Coherus Oncology, INC. | $77.26 | 2023-2025 | Loqtorzi |
| Adc Therapeutics America, INC. | $74.67 | 2021-2025 | |
| Dendreon Pharmaceuticals LLC | $74.61 | 2019-2025 | Provenge |
| Aveo Pharmaceuticals, INC. | $69.52 | 2022-2025 | Fotivda |
| Servier Pharmaceuticals LLC | $69.47 | 2022-2025 | |
| Taiho Oncology, INC. | $67.84 | 2023-2025 | |
| Kyowa Kirin, INC. | $59.18 | 2022-2023 | Poteligeo |
| Morphosys, US INC. | $57.94 | 2022 | |
| Kite Pharma, INC. | $55.06 | 2025 | Yescarta |
| Progenics Pharmaceuticals, INC. | $48.68 | 2024-2025 | |
| Mirati Therapeutics, INC. | $45.21 | 2023 | Krazati |
| G1 Therapeutics, INC. | $41.59 | 2022 | |
| Alnylam Pharmaceuticals INC. | $35.00 | 2023-2024 | Givlaari |
| Teva Pharmaceuticals USA, INC. | $34.55 | 2019 | |
| Geron Corporation | $33.92 | 2025 | Rytelo |
| Agios Pharmaceuticals, INC. | $32.80 | 2024-2025 | Pyrukynd |
| Boston Scientific Corporation | $29.56 | 2022 | |
| Pharmaessentia USA Corporation | $29.02 | 2022-2023 | Besremi |
| Eusa Pharma (US) LLC | $28.80 | 2022 | |
| Beone Medicines USA, INC. | $26.41 | 2025 | Tevimbra |
| Amag Pharmaceuticals, INC. | $25.53 | 2021 | |
| Fennec Pharmaceuticals, INC. | $25.45 | 2025 | Fyarro |
| Recordati_rare_diseases_inc. | $24.24 | 2024 | Sylvant |
| Azurity Pharmaceuticals, INC. | $23.43 | 2024 | Vivimusta |
| Secura Bio, INC. | $21.11 | 2023 | Copiktra |
| Heron Therapeutics, INC. | $20.48 | 2022 | |
| Cti Biopharma Corp. | $19.98 | 2023 | Vonjo |
| Deciphera Pharmaceuticals INC. | $16.81 | 2023 | Qinlock |
| Lexicon Pharmaceuticals, INC. | $16.25 | 2019 | |
| Menarini Silicon Biosystems, INC. | $15.66 | 2024 | |
| Emmaus Medical, INC. | $15.60 | 2022 | |
| Abbott Laboratories | $14.87 | 2023 | Proclaim |
| Blue Earth Diagnostics | $14.32 | 2021 | |
| Mylan Institutional INC. | $13.44 | 2019 | |
| Accord Healthcare, INC. | $12.96 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Flaherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.